Healthcare resource utilization and cost of pneumococcal disease in children in Germany, 2014–2019: a retrospective cohort study

Tianyan Hu, Bélène Podmore, Rosemarie Barnett, Dominik Beier, Wolfgang Galetzka, Nawab Qizilbash, Dennis Haeckl, Timo Boellinger, Jessica Weaver

Research output: Contribution to journalArticlepeer-review

Abstract

Background
Since the introduction of higher valency pneumococcal conjugate vaccines in 2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in Germany have been lacking. This study estimates healthcare resource utilization (HCRU) and medical cost associated with PDs in children 
Methods
A nationally representative sample from the Institute for Applied Health Research (InGef) German claims database was used, covering approximately 5% of the total German population. Episodes of pneumococcal pneumonia (PP), all-cause pneumonia (ACP), invasive pneumococcal disease (IPD), and acute otitis media (AOM) in children aged 
Results
During 2014–2019, 916,805 children aged 
Conclusions
The HCRU and cost per episode of pneumonia and IPD did not vary significantly from 2014–2019, but increased for AOM. The economic burden of pneumonia, IPD, and AOM remains substantial in Germany.
Original languageEnglish
Article number7 (2023)
JournalPneumonia
DOIs
Publication statusPublished - 25 Mar 2023

Fingerprint

Dive into the research topics of 'Healthcare resource utilization and cost of pneumococcal disease in children in Germany, 2014–2019: a retrospective cohort study'. Together they form a unique fingerprint.

Cite this